The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Neuropharmacology
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1396825
Identification of quality markers and optimization of processing of Gastrodiae rhizoma to treat brain diseases
Provisionally accepted
Yan Fu
1
Qing q. Xu
1
Jin q. Zhang
1
Chuan z. Kang
2
Chang g. Yang
1
Lu m. Guo
3
Cheng g. Zhang
1
Tao Zhou
1*
Cheng h. Xiao
1*- 1 Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China
- 2 China Academy of Chinese Medical Sciences, Beijing, Beijing Municipality, China
- 3 Other, Guizhou, China
Background: Gastrodiae rhizoma (GR), the dried tuber of Gastrodia elata Bl., has been used for centuries to treat brain diseases, such as Alzheimer's disease, major depressive disorder and cerebral ischemia. However, the processing of GR is complex and varied, resulting in unstable clinical treatment effects. The processing protocol can significantly affect the active ingredients and curative effects of GR. We can optimize the processing of GR by identifying quality markers to treat brain diseases. Methods: Fresh tuber of Gastrodia elata Bl. were processed in eight different protocols, and their resulting content in potentially bioactive compounds was compared using liquid chromatography-mass spectrometry and the potential quality markers of GR were screened by stoichiometric analysis. Potential quality markers of GR targeted Alzheimer's disease, major depressive disorder and cerebral ischemia were identified using network pharmacology. And the potentially neuroprotective effects of these components were validated through simulated docking to likely protein targets. Finally, the fit degree analysis was carried out by using different composition ratio and the proportion of disease component degree value, and the therapeutic effects of different processing methods on Alzheimer's disease, major depressive disorder and cerebral ischemia were clearly targeted.Results: We identified 32 potential therapeutic components and screened 13 quality markers in GR, five of these quality markers (Galactinol, Glucosyringic acid, Parishins C and E, and S-(4-hydroxybenzyl)-glutathione) show efficacy against all three brain diseasesbrain diseases, and steaming and microwave-drying during processing can optimize the component of these quality markers to treat these three brain diseases. Conclusion: The processing protocol can significantly affect the therapeutic components of GR, and may affect the effectiveness of GR in treating brain diseases. According to different therapeutic purposes of GR to adopt the corresponding optimal processing methods may improve its efficacy against brain diseases.
Keywords: Gastrodia elata BL, Fresh-cut processing, Q-makers, Neuroprotection, Metabolomics, Network Pharmacology
Received: 06 Mar 2024; Accepted: 10 Oct 2024.
Copyright: © 2024 Fu, Xu, Zhang, Kang, Yang, Guo, Zhang, Zhou and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Tao Zhou, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, Guizhou Province, China
Cheng h. Xiao, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, Guizhou Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.